ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028
TABLE OF CONTENTS
1. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY
INSIGHTS
2.2.1. COMMERCIAL
SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION
OF PREDICTIVE BIOMARKERS
2.2.3. FUSION
OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. KEY
BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY
& SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. INDUSTRY
COMPONENTS
2.8. REGULATORY
FRAMEWORK
2.9. KEY
MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT
LAUNCHES
2.9.3. CONTRACTS
& AGREEMENTS
2.10. MARKET
DRIVERS
2.10.1. INCREASE
IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING
PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING
PREVALENCE OF PRECISION MEDICINES
2.11. MARKET
CHALLENGES
2.11.1. WEAK
REIMBURSEMENT FRAMEWORK
2.11.2. COMMON
CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET
OPPORTUNITY
2.12.1. ONGOING
RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM
3.1. IN-SITU
HYBRIDIZATION
3.2. POLYMERASE
CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT
GENERATION SEQUENCING
3.5. OTHER
MECHANISMS
4. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS
DISEASES
4.4. OTHER
INDICATORS
5. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER
5.1. PHARMACEUTICAL
AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE
LABORATORIES
5.3. OTHER
CONSUMERS
6. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY
6.1. ASSAY
KITS AND REAGENTS
6.2. SOFTWARE
AND SERVICES
7. ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET - COUNTRY OUTLOOK
7.1. CHINA
7.2. JAPAN
7.3. INDIA
7.4. SOUTH
KOREA
7.5. ASEAN
COUNTRIES
7.6. AUSTRALIA
& NEW ZEALAND
7.7. REST
OF ASIA-PACIFIC
8. COMPETITIVE
LANDSCAPE
8.1. ABBOTT
LABORATORIES
8.2. ALMAC
GROUP
8.3. ARUP
LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER
CORPORATION
8.7. GE
HEALTHCARE
8.8. GENOMIC
HEALTH
8.9. ILLUMINA
INC
8.10. MYRIAD
GENETICS
8.11. QIAGEN
8.12. ROCHE
DIAGNOSTICS
8.13. SYSMEX
CORPORATION
8.14. THERMO
FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
LIST OF TABLES
TABLE 1: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR
SCORECARD
TABLE 3: LIST OF
ACQUISITIONS
TABLE 4: LIST OF
PRODUCT LAUNCHES
TABLE 5: LIST OF
CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF
CANCER PATIENTS IN 2020
TABLE 7: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY
COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE
POINTS
FIGURE 5: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $
MILLION)
FIGURE 7: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $
MILLION)
FIGURE 8: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $
MILLION)
FIGURE 10: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL
COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $
MILLION)
FIGURE 19: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $
MILLION)
FIGURE 22: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $
MILLION)
FIGURE 23: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: CHINA
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: JAPAN
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: INDIA
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: SOUTH KOREA
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: ASEAN
COUNTRIES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: AUSTRALIA
& NEW ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: REST OF
ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
Developing healthcare infrastructure to support the companion diagnostics
market’s development
MARKET
OUTLOOK
Triton’s research
report suggests that the Asia-Pacific companion diagnostics market is
anticipated to showcase a CAGR of 13.10% during the forecasted years 2022-2028.
China, India, Australia & New Zealand, Japan, ASEAN countries, South Korea,
and Rest of Asia-Pacific are considered in the region.
India is considered a
major emerging genomics market, with oncologists accepting biomarker-based tests.
The rising middle-class healthcare facilities and skilled practitioners have
driven the expansion of clinical diagnostics in the country. Besides this,
government hospitals like AIIMS and NIMHANS are striving to identify new
disease genes and biomarkers. Therefore, these factors are expected to fuel the
development of the companion diagnostics market across India over the forecast
period.
In South Korea, the
public healthcare system is offered to all citizens through the National Health
Insurance Corporation under the Ministry of Health and Wellness. As per WHO,
the Ministry is in charge of policies and supervision of the healthcare
systems. In this regard, the Health Insurance Review Agency reviews medical
charges, evaluating the overall healthcare system. The overall development of the
healthcare system supports the demand for companion diagnostics tests, driving
the South Korean market’s growth.
Get more insights into
the Asia-Pacific Companion Diagnostics Market:
https://www.tritonmarketresearch.com/reports/asia-pacific-companion-diagnostics-market
COMPETITIVE
OUTLOOK
The leading companies
in the companion diagnostics market include Almac Group, Biocartis, Abbott
Laboratories, Arup Laboratories, GE Healthcare, and Qiagen.
SEGMENTATION
1. ABBOTT
LABORATORIES
2. ALMAC
GROUP
3. ARUP
LABORATORIES
4. BIOCARTIS
5. BIOMERIEUX
6. DANAHER
CORPORATION
7. GE
HEALTHCARE
8. GENOMIC
HEALTH
9. ILLUMINA
INC
10. MYRIAD
GENETICS
11. QIAGEN
12. ROCHE
DIAGNOSTICS
13. SYSMEX
CORPORATION
14. THERMO
FISHER SCIENTIFIC
15. AGILENT
Comments
Post a Comment